RUNX1 and acute myeloid leukemia: In addition, we confirmed RUNX1, CBFβ/CM occupancy on the reported RUNX1 site42,43 as well as GATA2 binding to the reported GATA2 site42,43 in the human EGFL7 promoter by ChIP-qPCR using primary inv(16) AML CD34+ cells (Supplementary Fig. 1f).